Molecular Cloning and Characterization of a Novel Mouse Macrophage C-type Lectin, mMGL2, Which Has a Distinct Carbohydrate Specificity from mMGL1

Thandi M. Onami
*University of Tennessee - Knoxville*, tonami@utk.edu

M. Tsuiji
*University of Tokyo*

M. Fujimori
*University of Tokyo*

Y. Ohashi
*University of Tokyo*

N. Higashi
*University of Tokyo*

Follow this and additional works at: [https://trace.tennessee.edu/utk_micrpubs](https://trace.tennessee.edu/utk_micrpubs)

Recommended Citation
Onami, Thandi M.; Tsuiji, M.; Fujimori, M.; Ohashi, Y.; Higashi, N.; Hendrick, S. M.; and Irimura, T., "Molecular Cloning and Characterization of a Novel Mouse Macrophage C-type Lectin, mMGL2, Which Has a Distinct Carbohydrate Specificity from mMGL1" (2002). *Microbiology Publications and Other Works*. https://trace.tennessee.edu/utk_micrpubs/28

This Article is brought to you for free and open access by the Microbiology at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Microbiology Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact trace@utk.edu.
Authors
Thandi M. Onami, M. Tsuiji, M. Fujimori, Y. Ohashi, N. Higashi, S. M. Hendrick, and T. Irimura

This article is available at TRACE: Tennessee Research and Creative Exchange: https://trace.tennessee.edu/utk_micrpubs/28
Molecular Cloning and Characterization of a Novel Mouse Macrophage C-type Lectin, mMGL2, Which Has a Distinct Carbohydrate Specificity from mMGL1*

Makoto Tsuji, Mayuko Fujimori‡, Yoshimi Ohashi, Nobuaki Higashi, Thandi M. Onami§, Stephen M. Hedrick‡, and Tatsuro Irimura*†

From the Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo 7–3–1, Bunkyo-ku, Tokyo 113–0033, Japan and the §Cancer Center and the Division of Biology, University of California, San Diego, La Jolla, California 92037-1068

A novel mouse macrophage galactose-type C-type lectin 2 (mMGL2) was identified by BLAST analysis of expressed sequence tags. The sequence of mMGL2 is highly homologous to the mMGL, which should now be called mMGL1. The open reading frame of mMGL2 contains a sequence corresponding to a type II transmembrane protein with 332 amino acids having a single extracellular C-type lectin domain. The 3′-untranslated region included long terminal repeats of mouse early transponson. The MGL2 gene was cloned from a 129/SvJ mouse genomic library and sequenced. The gene spans 7,136 base pairs and consists of 10 exons, which is similar to the genomic organization of mMGL1. The reverse transcriptase-PCR analysis indicates that mMGL2 is expressed in cell lines and normal mouse tissues in a macrophage-restricted manner, also very similar to that of mMGL1. The mMGL2 mRNA was also detected in mMGL1-positive cells, which were sorted from thioglycollate-induced peritoneal cells with a mMGL1-specific monoclonal antibody, LOM-8.7. The soluble recombinant proteins of mMGL2 exhibited carbohydrate specificity for α- and β-GalNAc-conjugated soluble polyacrylamides, whereas mMGL1 preferentially bound Lewis X-conjugated soluble polyacrylamides in solid phase assays. These two lectins may function cooperatively as recognition and endocytic molecules on macrophages and related cells.

Macrophages (MØs)1 and related cells are widely distributed throughout the body, displaying a morphological and functional diversity. They are found in the lymphoid organs, liver, lungs, gastrointestinal tract, central nervous system, serous cavities, bones, synovia, and skin. Resident MØs mediate clearance of senescent or apoptotic cells, produce and secrete cytokines, are involved in hemopoiesis and bone resorption, transport and present antigens, and regulate neuroendocrine processes. Activated MØs are recruited to sites of infection, tissue injury, inflammation, and neoplasia and play crucial roles in tissue repair and pathogenesis (1).

The distribution and functional heterogeneity of MØs derive in part from their specialized plasma membrane receptors (2). Cell surface markers such as F4/80, sialoadhesin, MØ mannose receptor and scavenger receptor type A have significantly contributed to the current understanding of MØ ontogeny and function (3). However, in comparison to other immune cells such as B and T lymphocytes, relatively few MØ-restricted cell surface molecules have been identified. The physiological and pathological roles of these putative markers remain unknown.

Protein-carbohydrate interactions serve a variety of functions in the immune system. A number of lectins (carbohydrate-binding proteins) mediate both pathogen recognition and cell-to-cell interactions using structurally related carbohydrate recognition domains (CRDs). One of the most diversified families of these CRDs is Ca2+-dependent and termed C-type CRDs (4, 5). MØs and related cells such as dendritic cells are known to express several subfamilies of C-type lectins: type 1 multilectins such as MØ mannose receptor and lectins having type II transmembrane configurations such as MØ galactose-type (known previously as galactose/N-acetylglactosamine-specific) C-type lectin (MGL). These lectins seem to mediate carbohydrate-specific endocytosis (6–11). Little is known regarding the expression of selectins, another subfamily of C-type lectins, in MØs and related cells.

Previously, MGL was cloned from rats, mice, and humans and characterized. The lectin from mice was shown to have specific affinity for highly branched N-linked carbohydrate chains with terminal β-galactosyl groups and glycopeptides carrying three consecutive α-GalNAc-Ser/Thr (Tn-antigens) (12). A human MGL was also shown to have affinity for glycopeptides carrying three consecutive Tn-antigens (13). Surface protein receptor; BAC, bacterial artificial chromosome; BSA, bovine serum albumin; CRD, carbohydrate-recognition domain; DBPS, Dulbecco’s phosphate-buffered saline; HRP, horseradish peroxidase; MGL, macrophage galactose-type C-type lectin; RHL, rat hepatic lectin; RT, reverse transcriptase; TG-PEC, thioglycollate-induced peritoneal cells; RACE, rapid amplification of cDNA ends; STAT, signal transducers and activators of transcription; mAb, monoclonal antibody; MES, 4-morpholineethanesulfonic acid; MOPS, 4-morpholinepropanesulfonic acid; h, human; m, mouse; r, rat.

* This work was supported by grants-in-aid from the Ministry of Education, Science, and Technology, and from the Program for Promotion of Basic Technology of the Ministry of Education, Culture, Sports, Science, and Technology of Japan (09254101, 11557180, 11672162, and 12307054), from the Research Association for Biotechnology, Special Coordination Funds for Promoting Science and Technology of the Ministry of Education, Culture, Sports, Science, and Technology, and from the Program for Promotion of Basic Research Activities for Innovative Biosciences. The costs of publication of this article were defrayed in part by the payment of page charges. The nucleotide sequence(s) reported in this paper has been submitted to the DDBJ/GenBank™/EMBL Data Bank with accession number(s) AY103461, AY103462.

† Present address: Dept. of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.
‡ To whom correspondence should be addressed. Tel.: 813-5841-4870; Fax: 813-5841-4879; E-mail: irimura@mol.f.u-tokyo.ac.jp.
§ To whom correspondence should be addressed. Tel.: 818-5841-4870; Fax: 813-5841-4879; E-mail: irimura@mol.f.u-tokyo.ac.jp.

Vol. 277, No. 32, Issue of August 9, pp. 28892–28901, 2002
Received for publication, April 18, 2002, and in revised form, May 16, 2002
Published, JBC Papers in Press, May 16, 2002, DOI 10.1074/jbc.M203774200
Printed in U.S.A.
Characterization of mMGL2

plasmid resonance revealed that affinity of recombinant hMGL for immobilized glycopeptides increased in parallel with the number of GalNAc residues (14). Tn-antigen was known as a marker of malignant cells, and MGL was shown to play a role as a recognition molecule on M0s for tumor cells (15–17). Immunohistochemical localization of mouse MGL (mMGL) with specific monoclonal antibodies revealed that this lectin has a strong association with M0s residing in connective tissue and those infiltrated into tumor tissues (18–20). Recent studies demonstrated that this lectin is also expressed on the surface of immature dendritic cells and is involved in the uptake of glycosylated antigens in mice and humans (21, 22).

A C-type lectin highly homologous to MGL and expressed mainly on hepatocytes, the hepatic asialoglycoprotein receptor (ASGR), has two isomers in mice, rats, and humans, apparently due to recent gene duplication. Previously, MGL was believed to have a single gene. Southern blotting analysis supported this notion. However, in this report, we describe the properties of another novel M0 galactose-type C-type lectin, mMGL2. As an obvious consequence, the previous mMGL must now be called mMGL1. These lectins are highly homologous to each other except in their cytoplasmic domains and CRDs. We found that mMGL2 has a distinct carbohydrate specificity from mMGL1. These lectins seem to be expressed on the same cells and therefore seem to function cooperatively.

**EXPERIMENTAL PROCEDURES**

**Cells**—The following cell lines were provided by Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer Tohoku University, Sendai, Japan: L929, JLS-V9, EL4, RL-1, YAC-1, BCL-1-2B0, P815, P388, and M1 cells. RAW264.7 cells were purchased from TCC from ATCC. All cells were cultured in RPMI 1640 media with 10% fetal calf serum at 37 °C with 5% CO2.

Thioglycollate-induced peritoneal cells (TG-PEC) were obtained from 6–8-week-old female C57BL/6J mice from Clea Japan, Inc (Kawasaki, Japan). These were maintained under pathogen-free conditions. These mice received 1 ml of 4% thioglycollate broth (Difco, Detroit, MI) by intraperitoneal injection. Four days later, mice were sacrificed by neck dislocation, and peritoneal exudate cells were harvested by lavage with 5 ml of RPMI 1640 media on ice.

TG-PEC were suspended in chilled 0.1% BSA/Dulbecco’s modified phosphate-buffered saline (DBPS: 137 mM NaCl, 13.4 mM KCl, 4.5 mM Na2HPO4, 7.35 mM KH2PO4, 0.49 mM MgCl2, 0.905 mM CaCl2) containing phycoerythrin-labeled mAb LOM-14 (reactive with mMGL1 and another novel M0 lectin, mMGL2, designated as a recognition molecule on M0s). These lectins are highly homologous to each other except in their cytoplasmic domains and CRDs. We found that mMGL2 has a distinct carbohydrate specificity from mMGL1. These lectins seem to be expressed on the same cells and therefore seem to function cooperatively.

**Rapid Amplification of cDNA Ends (RACE)**—The poly(A)+ RNA from RAW264.7 cells were isolated using a μMACS RNA isolation kit (Miltenyi Biotec). Adapter-ligated cDNA were synthesized using the Marathon cDNA amplification kit (CLONTECH). To obtain full-length cDNA of mMGL2, an antisense primer, AS5 (5’-TCTCTCCA-CATCCACTTCCAGAG-3’), and a sense primer, S5 (5’-TGGGAGGG-GAAAGAAAACCCG-3’), were designed from the expressed sequence tag clones for 5’-RACE and 3’-RACE reactions, respectively. Both primers were incubated at 95 °C for 10 min and hybridized by 43 cycles at 94 °C for 45 s, 60 °C for 45 s, and 72 °C for 2 min. The resulting 1.5-kbp and 700-bp products were subcloned into the pGEM-T easy vector (Promega UK, Southampton, UK) and sequenced with the dye primer method.

**Screening of the Genomic Clone Coded the mMGL2 Gene**—A 128/SvJ mouse genomic vector cDNA library was screened with the complete mMGL2 cDNA coding sequence labeled by random priming with [32P] by plaque hybridization. The fragments of positive clones were subcloned into pBluescript SK+ (Stratagene). These clones were sequenced with 24 specific primers with the dye-terminator method. These sequences were assembled and aligned using Genetyx-Mac.

**Production and Isolation of Soluble mMGL2**—cDNA encoding mMGL1 and mMGL2 was cloned into pGEM-T easy vector (Promega). The vector was digested with BamHI and SacI (for mMGL1) or BamHI and NotI (for mMGL2). The fragments encoding these neck and CRD domains were separated with agarose gel electrophoresis and inserted into each site of expression plasmid vector pET-21a (Novagen). The BL21(DE3) cells containing the plasmid were grown to mid-log phase at 37 °C in 500 ml of LB TY medium (12 liters) and then treated with isopropyl β-D-thiogalactoside at a concentration of 1 mM. After isopropyl β-D-thiogalactopyranoside induction, the cultured cells were washed with 50 mM Tris- HCl pH 8.0, containing 0.15 mM NaCl (TBS) and suspended in TBS containing phenylmethanesulfonyl fluoride. The cell lysates were prepared by freezing and thawing, and after the addition of DNase I (final 50 units/ml) and lysozyme (final 0.2 mg/ml), they were incubated 1 h at 37 °C and then centrifuged at 15,000 × g for 10 min at 4 °C. Expression products formed inclusion bodies. The pellets were washed with TBS containing 0.5% Triton X-100 and 10 mM EDTA and then with H2O. The washed pellets were solubilized with 2 mM NH4OH (20 ml) and then added to 25 mM MOPS buffer, pH 7.0, containing 2 mM glutathione, reduced form, 0.2 mM glutathione oxidized form, 20 mM CaCl2, 0.5 mM NaCl, and 0.02% NaN3 (20 ml). These solutions were then dialyzed against 25 mM MOPS buffer, pH 7.0, containing 20 mM CaCl2, 0.5 mM NaCl, and 0.02% NaN3. Soluble recombinant mMGL1 and mMGL2 were purified by affinity chromatography on a column of galactose-Sepharose 4B, as described previously (24).

**Solid Phase Binding Assays**—Absorption of the purified soluble recombinant mMGL1 or mMGL2 onto enzyme-linked immunosorbent assay plates was carried out (655061, Greiner Bio-One). One hundred microliters of solution (3 μg/ml in DBPS) to each well and incubating the plates for 18 h at 4 °C. After blocking of the wells using 3% bovine serum albumin (BSA) in DBPS for 2 h at room temperature, 150 μl solution of biotinylated soluble polycalyxamide with attached mono- or oligosaccharides (GlycoTech, Rockville, MD) or hybridoma culture supernatant, diluted into varying concentrations with DBPS containing 5% BSA, were added to each well. After incubation for 2 h at 4 °C (at room temperature), the wells were washed three times with DBPS to remove unbound materials, and then 100 μl of HRP-conjugated streptavidin solution (1.25 μg/ml in DBPS) or HRP-conjugated goat anti-rat IgG (H + L) solution (0.375 μg/ml in DBPS) for rat mAbs was added to detect bound materials. After incubation for 1 h at room temperature, the wells were washed three times with DBPS. Subsequently, 100 μl of 1:2000 diluted ABTS solution containing 0.34% H2O2 in 0.1 M sodium citrate buffer (pH 4.3) was added, and the absorbance was measured at 405 nm on a microplate reader (25).

To determine pH dependence of the binding of mMGL1 and mMGL2, the incubation conditions were modified as follows. After the blocking buffer was removed, the wells were washed three times with DBPS. Aliquots (50 μl) of biotinylated soluble polycalyxamide in 2 × incubation buffer (274 mM NaCl, 26.8 mM KCl, 0.98 mM MgCl2, 1.810 mM CaCl2, 2% BSA) were mixed with equal volumes of 2 × pH buffer (50 mM sodium acetate buffer at pH 4.5–6.0, 50 mM MES buffer at pH 6.0–7.0, 50 mM HCl–HCl buffer at pH 7.0–8.0) and transferred to each well. Incubation was performed at 4 °C for 2 h. After washing the wells three times with DBPS containing 0.1% Tween 20 and 100 μl of HRP-conjugated streptavidin solution (Zymed Laboratories Inc., 1000 × in DBPS containing 1% BSA) was added and incubated for 1 h at 4 °C. The wells were emptied and washed three times with DBPS, and then 100 μl of ABTS solution containing 0.34% H2O2 in 0.1 M sodium citrate buffer, pH 4.2) was added, and absorbance at 405 nm was determined.
Characterization of mMGL2

A

The nucleotide sequence of the mMGL2 cDNA.

A, the nucleotide sequence of the mMGL2 cDNA and its deduced amino acid sequence. The putative transmembrane domain is underlined. The poly-A addition signal is underlined with a broken line. The potential N-glycosylation site is underlined with a wavy line. The putative internalization signal is boxed.

B

Asterisks mark the amino acid residues conserved in both lectins. Arrows indicate boundaries of exons.

Fig. 1. The nucleotide sequence of the mMGL2 cDNA. A, the nucleotide sequence of the mMGL2 cDNA and its deduced amino acid sequence. The putative transmembrane domain is underlined. The poly-A addition signal is underlined with a broken line. The potential N-glycosylation site is underlined with a wavy line. The putative internalization signal is boxed. B, amino acid sequences of mMGL1 and mMGL2.
Immunohistochemical Staining—MGL-positive cells were immunohistochemically detected in the skin as described previously (19). In brief, skin samples freshly prepared from Mgl1/H11002/H11002 mice and their littermates were embedded in OCT compound (Miles, Elkhart, IN) and frozen in a liquid nitrogen bath. Cryostat sections (10 μm thick) were picked up on poly-L-lysine-coated slides and fixed in ice-cold acetone for 10 min. Nonspecific bindings were blocked using a blocking solution (2% normal mouse serum and 3% BSA in DPBS) for 10 min. The sections were treated with the first antibodies for 1 h and then treated with biotinylated mAb mouse anti-rat and (1⁄50 dilution) for 30 min and finally treated with alkaline phosphatase-streptavidin (1⁄100 dilution) for 30 min. The staining was visualized using Histomark Red, and the cell nucleus was counterstained in Mayer’s hematoxylin after post-fixation using 2% glutaraldehyde in DPBS. The sections were observed under a light microscope (TMD-300, Nikon, Tokyo, Japan).

RESULTS

Cloning of a Novel Macrophage C-type Lectin—We found four clones (GenBank accession numbers AA511511, AA537107, AA671707, and AA498512) similar to mMGL (mMGL1, GenBank accession number S36676) and hMGL (HML-2, GenBank accession number D50532) in the database of mouse expressed sequence tag. To obtain the full sequences of a novel C-type lectin, 5'- and 3'-RACE reactions were performed using mRNA from RAW264.7 cells as a template and with specific primers designed to match these expressed sequence tags. The full-length cDNA was prepared by RT-PCR of poly(A)+ RNA from RAW264.7 cells. The obtained full-length cDNA (GenBank accession number AY103461) encodes an open reading frame of 996 base pairs, predicting a protein of 332 amino acid residues (38,067 Da), which we subsequently termed mMGL2. The 3'-untranscription region has a sequence of long terminal repeat (LTR) of mouse early transposon (26, 27). The nucleotide sequence of mMGL2 has 79.0 and 54.9% identity with that of mMGL1 and hMGL (HML-2), respectively. The amino acid sequence of mMGL2 has 91.5 and 51.8% identity with that of mMGL1 and hMGL (HML-2), respectively. The neck domain is highly homologous to mMGL1 at 95.3%. Only five residues (Ile-87, Asn-108, Leu-144, Glu-166, and Thr-167) were different in the neck domain from Arg-78 to Gly-183. Amino acids within the CRD (corresponding to exons 8–10), particularly those corresponding to the last exon (exon 10), showed differences between mMGL1 and mMGL2. In the sequence of cytoplasmic domain (corresponding to exon 2), mMGL2 has a putative internalization signal (YXX) and an insertion of extra 14 amino acid residues. A consensus sequence for polyadenylation signal is present in nucleotides 1467–1472 followed by a poly(A) tail. There are two potential N-glycosylation sites (Fig. 1), both in mMGL1 and -2.

Genomic Structure and Chromosome Location of mMGL2—Screening of a 129/SvJ mouse genomic library led to the isolation of three clones. Two clones (termed 92b and 41b) were

![Genomic structure of Mgl2 gene. As shown in A, the gene spans 7136 bp and consists of 10 exons and is similar to Mgl1 in genomic organization. The untranslated regions are shown as closed boxes, and the coding regions are shown as hatched boxes. The initiation codon is within the second exon. B, the linkage of BAC clones. We identified the BAC clone RPCI-23-172M21, which encodes the Mgl2, Asgr1, and Asgr2 genes. RPCI-23-198E14 encodes Mgl2 and Mgl1. C, the promoter sequences of Mgl2 gene. Transcription factor binding site consensus sequences were searched using the transcription factor database (www.cbrc.jp/research/db/TFSEARCH.html).]
Characterization of mMGL2

included in the Mgl (Mgl1) gene (GenBank™ accession number AF132744) (29), but the other clone (termed 41a) was included in the Mgl2 gene, confirmed by PCR using primers of mMGL2. The latter gene spans 7136 bp, consists of 10 exons, and is similar to Mgl (Mgl1) in genomic organization (Fig. 2A). The GenBank™ accession number of the Mgl2 gene is AY103462. The intron/exon boundaries were defined using DNA sequencing. All splice sites conform to the AG/GT rule (Table I). This clone contains 5'-upstream sequences. To identify the promoter sequences of the Mgl2 gene, transcription factor binding site consensus sequences were searched using the transcription factor data base (www.cbrc.jp/research/db/TFSEARCH.html). The promoter lacks a classical TATA box but contains several binding sites for other transcription factors, C/EBPβ, CF1, AML-1, c-Ets, PU.1, c-Rel, Oct-1, Lyf-1, AP-1, GATAs, and STATs. These features are almost identical to that of the 5'-flanking motifs of the Mgl1 gene. These are the sites found upstream of genes expressed preferentially by cells of monocyte/MØ lineages (Fig. 2C).

We identified the BAC clone RPCI-23–172M21, which coded the Mgl2, Asgr1, and Asgr2 genes. The other clone RPCI-23–198E14 encodes the Mgl2 and Mgl1 genes. These BAC clones have been constructed from the genomic DNA of female C57BL/6J mice. Therefore, these four C-type lectin genes should be located within about 150 kb on mouse chromosome 11 (Fig. 2B).

Reactivity with Monoclonal Antibodies—Previously, we have obtained mAbs specific for MGL1 using purified mMGL (likely to be a mixture of mMGL1 and mMGL2) and recombinant MGL1 as immunogens. Screening to obtain specific monoclonal antibodies was performed previously with recombinant mMGL1 (25). The antibodies are mAb LOM-4.7, mAb LOM-8.2, mAb LOM-8.7, all shown to have blocking activity, mAb LOM-11, shown to recognize the ligand-induced binding site, and a non-blocking mAb LOM-14 (25, 30). As shown in Fig. 3, mAb LOM-4.7, mAb LOM-8.2, mAb LOM-8.7, and mAb LOM-11 were shown to be specific for MGL1. LOM-14 bound to both MGL1 and MGL2 (Fig. 3). These results suggested that the most diverse region of these lectins was the ligand binding site.

Distribution of mMGL2 mRNA in Tissue and Cells—As a means of testing the expression profiles of this putative gene and mMgl1, RT-PCR analysis was performed on 10 mouse cell lines including L929 (fibroblast line), JLS-V9 (fibroblast-like bone marrow-derived cell line), EL4 (thymoma cell line), RL-3 (lymphoma cell line), YAC-1 (lymphoma cell line), BCL1-B20 (malignant B cells), P815 (mastocytoma cells), P388 (MØ-like lymphoid cell line), M1 (myeloblastic leukemia cells), and RAW264.7 (MØ-like cell line). The 644-bp bands indicating mMgl2 were found only in the cell lines

### Table I

| Exon no. | Position in coding sequence | Size | Acceptor sequence | Donor sequence | Intron length | Intron phase |
|----------|-----------------------------|------|-------------------|----------------|---------------|-------------|
| 1        | 1–23 bp                     | 23   | CACAGgtaac        | TCTAAGtag     | 3684 bp       | 1           |
| 2        | 24–168 bp                   | 145  | ttcagTTCTG        | TCTAATCTG     | 787 bp        | 1           |
| 3        | 169–279 bp                  | 111  | agcgTTCTCT        | CGGAgggtg     | 428 bp        | 1           |
| 4        | 280–375 bp                  | 96   | atcgATTCC         | CAGGAgggtg    | 83 bp         | 1           |
| 5        | 376–447 bp                  | 72   | ttcagCTGAC        | GCCAgggtg     | 79 bp         | 1           |
| 6        | 448–519 bp                  | 72   | ttcagGCCTGG       | AACAGgtg      | 258 bp        | 1           |
| 7        | 520–606 bp                  | 87   | ccagATTCTG        | CAAAGgtg      | 103 bp        | 1           |
| 8        | 607–758 bp                  | 152  | cgtagCTGCG        | AGCAAGgtg     | 77 bp         | 0           |
| 9        | 759–865 bp                  | 107  | ttagAATTT         | TCTAAGtag     | 144 bp        | 2           |
| 10       | 866–1530 bp                 | 629  | ttcagGAATT        |                  |               |             |

* Exon positions in coding sequence.

---

**Fig. 3. Binding of mAbs to the recombinant mMGL1 and mMGL2.** The binding of mAbs LOM-4.7, LOM-8.2, LOM-8.7, LOM-11, and LOM-14 to the immobilized recombinant MGL1 (A) and MGL2 (B) was measured according to mAb concentration. The binding of mAbs was detected using HRP-conjugated goat mAbs specific for rat IgG (H + L). Absorbance at 405 nm was measured on a microplate reader. The values represent means of triplicate determinations, and the error bars indicate S.D.

P388 and RAW264.7 (Fig. 4A). These cell lines were also high expressers of mMgl1. To assess the expression patterns of mMgl1 and mMgl2 in vivo, RT-PCR analysis was conducted...
FIG. 4. RT-PCR analysis of mMGL1 and mMGL2 mRNA expression in cells and tissue. A, the cDNA was prepared from mouse cell lines (L929, JLS-V9, EL4, RLδ1, YAC-1, BCL1-B20, P815, P388, RAW264.7, and M1). B, tissue cDNA (CLONTECH) was used after normalizing the relative amounts according to the levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA. C, TG-PEC were analyzed for the binding of mAbs LOM-14 and LOM-8.7. The cells highly or poorly reactive with mAb LOM-8.7 were separated and tested for mAb LOM-14 binding by flow cytometry. cDNA was prepared from the sorted cells, and RT-PCR analysis was performed. The PCR products were then separated on 1% agarose gels, stained with ethidium bromide, and visualized with the image analyzer. The ratios of band intensity of PCR products were measured. The panels represent a typical result of two separate experiments including cell fractionations. The results of these two separate experiments were almost identical.
on RNA isolated from 13 different normal mouse tissues and embryos (Fig. 4B). These genes were expressed almost throughout the body, and the apparent relative intensities among different organs were similar between mMgl1 and mMgl2. To assess whether the expression levels of these genes correspond at single cell levels, TG-PEC were sorted for the binding of mAb LOM-8.7, an mAb specific for mMGL1, and then reacted with mAb LOM-14 reactive with both mMGL1 and mMGL2. As shown in Fig. 4C, cells strongly reactive with mAb LOM-8.7 were also reactive with mAb LOM-14. The ratios of expressed mRNAs corresponding to mMgl1 and mMgl2 shown by RT-PCR analysis were almost identical when unsorted mAb LOM-8.7-positive and mAb LOM-8.7-negative cells were compared. These results indicate that the mMgl1-positive cells also express the mMgl2 mRNA.

mMGL2-positive Cells in Tissue Sections from Mgl1−/− Mice—Frozen sections of skins from Mgl1−/− and Mgl1+/− mice were stained with mAb LOM-8.7 and mAb LOM-14 (Fig. 5). The results revealed that Mgl1−/− mice expressed epitopes reactive with mAb LOM-14 at lower levels than Mgl1+/− mice but not with mAb LOM-8.7. These epitopes are likely to represent mMGL2. The subcellular localization of the mAb LOM-14 staining in Mgl1−/− mice did not appear to be distinct from that of mAb LOM-8.7 staining in Mgl1+/− mice.

Carbohydrate Specificity of mMGL2—A variety of biotin-labeled soluble polyacrylamides with mono- or oligosaccharides were applied to determine the carbohydrate specificity of mMGL1 and mMGL2 (Fig. 6). The carbohydrates tested are listed in the figure. The recombinant form of mMGL1 had the highest affinity with Leα residues among all carbohydrate-modified polyacrylamides tested. mMGL2 showed a very low affinity with Leα but showed the highest affinity with β-linked GalNAc residues (Fig. 6). The bindings were inhibited with 5 mM EDTA (data not shown).

pH-dependent Binding of Ligands to mMGL—Enzyme-linked immunosorbent assays were performed under various pH conditions to determine the binding of soluble polyacrylamides with Leα residues or α-GalNAc residues to immobilized recombinant mMGL1 or mMGL2, respectively. Under a Ca2+ concentration similar to that found in extracellular fluids (0.905 mM), the binding decreased when pH was lowered from extracellular (pH 7.3) to endosomal (pH 5.4). The profiles of the pH-dependent binding were similar to that observed with intact hepatic asialoglycoprotein receptors (31). The pH value of a half-maximal ligand binding, designated as pH50, was 5.5 for MGL1 and 5.7 for MGL2 (Fig. 7).

DISCUSSION

In the present study, we found a novel M0 C-type lectin, mMGL2, and characterized its genomic structure, expression patterns, and carbohydrate specificitity. The Mgl2 gene spans 7136 bp and consists of 10 exons, which is a similar genomic organization to that of the Mgl1 gene now renamed the Mgl1 gene. We reported that the Mgl1 gene linked to Trp53 and is located 1.8 ± 1.2 cM distal to D11Mit5 and 1.8 ± 1.2 cM proximal to Htt on mouse chromosome 11. Using a panel of DNA samples from two parental mice, C3H/Hej-gld and (C3H/Hej-gld × Mus spretus) F1 were digested with various restriction endonucleases and hybridized with a MGL1 cDNA probe to determine the restriction fragment length polymorphism and to allow haplotype analyses (29). The hepatic asialoglycoprotein receptor genes (Asgr1 and Asgr2) were also known to be linked to Trp53 (32). We found BAC clones, which included these two C-type lectins. These results indicate that the highly homologous Mgl2 gene is linked within about 50 kb. Their homology and close genomic localization indicate that the original gene was duplicated recently. The human MGL (HML-2) gene was mapped in chromosome 17p and linked to ASGR1 and ASGR2. These results show that there is a cluster of type 2 C-type lectin genes on mouse chromosome 11 and on human 17p12–13. Likewise, the natural killer gene complex resided on mouse chromosome 6 and on human 12p (33, 34).

Although there was a high degree of sequence homology between MGL1 and MGL2, the sequences corresponding to cytoplasmic and CRD showed differences, suggesting that cytoplasmic tail associations and the carbohydrate recognitions are unique between MGL1 and MGL2. We showed that recombinant MGL1 bound soluble polyacrylamides containing Leα oligosaccharides. MGL2 had affinity with polycarbohydrates containing α- or β-GalNAc. It has been believed that C-type lectins contain a peptide segment that corresponds to the carbohydrate binding specificity within the CRD and that the sequence in Gal and GalNAc-binding lectins, such as ASGRs, is QPD. In contrast, the sequence in mannose-, fucose-, and GlcNAc specific lectins, such as serum mannose-binding proteins, was EPN. The sequence in both MGL1 and -2 was QPD. However, it was obvious from our results that their fine specificities depended on other amino acids in the CRD (Figs. 6 and 8). Some of the amino acid residues important in the
Carbohydrate recognitions were conserved in mMGL1, mMGL2, hMGL, RHL-1 and -2, mASGR-1, and hASGR-1. Crystallographic determination of the structure of human ASGR-1 revealed amino acid residues important in sugar binding (35). Furthermore, rat hepatic asialoglycoprotein receptor was subjected to site-directed mutation. As a result, the pH dependence of ligand binding was shown to be mediated by His-256, Asp-266, and Arg-270 (36). Because these residues are also conserved in mMGL1 and -2, they should also be responsible for their pH dependence (Fig. 8). Amino acid residues responsible for the differential carbohydrate specificity between mMGL1 and -2 and other members of the C-type lectin family and the phylogeny of these lectins (Fig. 8) are yet to be elucidated.

There is a possibility that mMGL1 and -2 form heterooligomers. These lectins are known to form trimeric structures through the interactions of the neck domain in a similar manner to that of ASGRs. ASGRs are abundantly expressed on the sinusoidal surface of hepatic parenchymal cells (37, 38). Its primary role is the removal and degradation of desialylated glycoproteins from circulation. High affinity binding requires the receptor to be assembled as a heterooligomer consisting of two highly homologous subunits, termed hepatic lectin 1 and 2 (39). Experiments with recombinant rat hepatic lectins suggested that the binding properties of the major subunit (RHL-1) and the minor subunit (RHL-2/-3) were optimized for different ligands (40). In the case of mMGL1 and -2, the recombinant form corresponding to each one showed affinity with different carbohydrates, indicating that heterooligomer formation was not required for their carbohydrate recognition. However, these lectins were likely to be expressed on the same cells at the single cell level and cooperatively functioned to recognize and uptake extracellular molecules.

mMGL1-positive cells are abundant in connective tissues throughout the body (19). mMGL1 was shown to be expressed on the surfaces of bone marrow-derived immature dendritic cells (21). hMGL is also shown to be expressed on monocyte-derived immature dendritic cells and monocyte-derived immature MØs in humans (41). We have shown that mMGL1-positive cells migrate from dermis to regional lymph nodes during the sensitization phase of contact hypersensitivity (42).
FIG. 8. Comparison of the amino acid sequences of the CRD of C-type lectins. A, multialignment of the CRD sequences of C-type lectins. B, evolutionary tree of sequence of CRD of C-type lectins. Abbreviations used in this figure are: MHL, mouse hepatic lectin; rKCR, rat Kupffer cell receptor; mKCR, mouse Kupffer cell receptor.
migration was initiated by cytokine-mediated release of mMGL1-positive cells from dermis (42–44). The cells homed to the boundary of the T-cell area in the regional lymph nodes, and the prevention of migration seemed to interfere with sensitization. Involvement of coordinated functions of mMGL1 and -2 in such pathogenic processes should be the most important subject of future investigations.

REFERENCES

1. Lewis, C., and McGee, J. O. D. (1992) The Macrophage: The Natural Immune System, pp. 1–413. IRL Press at Oxford University Press, Oxford
2. Feizi, T. (2000) Immunol. Rev. 173, 79–88
3. McKnight, A. J., and Gordon, S. (1998) Adv. Immunol. 68, 271–314
4. Linehan, S. A., Martinez-Pomares, L., and Gordon, S. (2000) Microbes Infect. 2, 279–288
5. Weis, W. I., Taylor, M. E., and Drickamer, K. (1998) Immunol. Rev. 163, 19–34
6. Stahl, P. D., and Ezekowitz, R. A. (1998) J Biol. Chem. 273, 1567–1573
7. Liu, Y., Chirino, A. J., Misulovin, Z., Leteux, C., Feizi, T., Nussenzweig, M. C., and Bjorkman, P. J. (2000) J. Exp. Med. 191, 1105–1116
8. Leteux, C., Chai, W., Loveless, R. W., Yuen, C. T., Uhlin-Hansen, L., Combarou, Y., Jankovic, M., Marie, S. C., Misulovin, Z., Nussenzweig, M. C., and Ten, F. (2000) J. Exp. Med. 191, 1117–1126
9. Ozaki, K., Ii, M., Itoh, N., and Kawasaki, T. (1992) J. Biol. Chem. 267, 9229–9235
10. Kawakami, K., Yamamoto, K., Toyoshima, S., Osawa, T., and Irimura, T. (1995) Jpn. J. Cancer Res. 86, 744–749
11. Valladeau, J., Duvert-Frances, V., Pin, J. J., Kleijmeer, M. J., Ait-Yahia, S., Meier, M., Bider, M. D., Malashkevich, V. N., Spiess, M., and Burkhard, P. (2000) J. Biol. Chem. 275, 857–865
12. Ouyang, H., Tailor, M. E., and Drickamer, K. (2000) J. Biol. Chem. 275, 1143–1153
13. Nakamura, K., Imai, Y., and Irimura, T. (1996) J. Immunol. 156, 128–135
14. Iida, S., Yamamoto, K., and Irimura, T. (1999) J. Biol. Chem. 274, 10697–10705
15. Sakamoto, T., Imai, Y., and Irimura, T. (1995) J. Leukocyte Biol. 57, 407–414
16. Ichii, S., Imai, Y., and Irimura, T. (1997) J. Leukocyte Biol. 62, 761–770
17. Ichii, S., Imai, Y., and Irimura, T. (2000) Cancer Immunol. Immunother. 49, 1–9
18. Imai, Y., Akimoto, Y., Mizuochi, S., Kimura, T., Hirano, H., and Irimura, T. (1995) Immunology 86, 591–598
19. Mizuochi, S., Akimoto, Y., Imai, Y., Hirano, H., and Irimura, T. (1997) Glyobiology 7, 137–146
20. Mizuochi, S., Akimoto, Y., Imai, Y., Hirano, H., and Irimura, T. (1998) Glycoconj. J. 15, 379–404
21. Denda-Nagai, K., Kubota, N., Tsuiji, M., Kamata, M., and Irimura, T. (2002) Immunol. Rev. 188, 145–153
22. Higashi, N., Fujikawa, K., Denda-Nagai, K., Hashimoto, S., Naga, S., Sato, T., Fujita, Y., Morikawa, A., Tsuiji, M., Miyayaka, N., Sano, Y., Suzuki, N., Yamamoto, K., Matsushita, K., and Irimura, T. (2002) J. Biol. Chem. 277, 20686–20693
23. Onami, T., Lin M.Y., Page, D. M., Reynolds, S. A., Katayama, C. D., Marib, J. D., Irimura, T., Varki, A., Varki, N., and Hedrick, S. M. (2002) Mol. Cell. Biol. 22, 5173–5181
24. Sato, M., Kawakami, K., Osawa, T., and Toyoshima, S. (1992) J Biochem. (Tokyo) 111, 331–336
25. Kimura, T., Imai, Y., and Irimura, T. (1995) J. Biol. Chem. 270, 16056–16062
26. Tanaka, I., and Ishihara, H. (2001) Virology 280, 107–114
27. Mager, D. L., and Freeman, J. D. (2000) J. Virol. 74, 7221–7229
28. Trowbridge, I. S. (1991) Curr. Opin. Immunol. 1, 55–62
29. Tsuiji, M., Fujimori, M., Seldin, M. F., Taketo, M. M., and Irimura, T. (1999) Glycoconjug. J. 16, 1073–1082
30. Kimura, T., Hosoi, T., Yamamoto, K., Suzuki, N., Imai, Y., and Irimura, T. (2000) Mol. Immunol. 37, 151–160
31. Hudin, R. L., Pricer, W. E., Jr., Ashwell, G., Stockert, R. J., and Morell, A. G. (1974) J Biol. Chem. 249, 5536–5543
32. Blackburn, P. C., Griffith, J., and Morahan, G. (1995) Genomics 26, 308–317
33. Yokoyama, W. M., and Seaman, W. R. (1995) Annu. Rev. Immunol. 11, 341–363
34. Brown, M. G., Fulmek, S., Matsumoto, K., Cho, R., Lyons, P. A., Levy, E. R., Scalzo, A. A., and Yokoyama, W. M. (1997) Genomics 42, 16–25
35. Meier, M., Bider, M. D., Malashkevich, V. N., Spiess, M., and Burkhard, P. (2000) J. Mol. Biol. 300, 857–865
36. Wragg, S., and Drickamer, K. (1999) J. Biol. Chem. 274, 35400–35406
37. Collins, J. C., Stockert, R. J., and Morell, A. G. (1984) Hepatology 4, 80–83
38. Braun, J. R., Willnow, T. E., Ishibashi, S., Ashwell, G., and Herz, J. (1996) J. Biol. Chem. 271, 21160–21166
39. Bider, M. D., and Spiess, M. (1998) FEBS Lett. 434, 37–41
40. Ruiz, N. I., and Drickamer, K. (1996) Glycoconjug. J. 13, 555–569
41. Higashi, N., Morikawa, A., Fujikawa, K., Fujita, Y., Sano, Y., Miyayaka, N., Suzuki, N., Yamamoto, K., Matsushita, K., and Irimura, T. (2002) Int. Immunol. 14, 545–554
42. Sato, K., Imai, Y., and Irimura, T. (1998) J. Immunol. 161, 6835–6844
43. Chun, K. H., Imai, Y., Higashi, N., Irimura, T. (2000) J. Leukocyte Biol. 68, 471–478
44. Chun, K. H., Imai, Y., Higashi, N., Irimura, T. (2000) Int. Immunol. 12, 1695–1703